IPOPI
14 August 2023, Geneva, Switzerland - We are pleased to announce that UNITAR, the United Nations Institute for Training and Research, and IPOPI, the International Patient Organization for Primary Immunodeficiencies, have entered into a new Memorandum of Understanding (MoU). This agreement represents a strong commitment to collaborating and cooperating to make a positive impact on access to plasma-derived therapies worldwide.
The MoU enhances our existing collaboration, elevating it to a true partnership. It promotes cooperation through various means, such as knowledge sharing, innovative education, training, capacity-building solutions, and raising awareness to improve access to healthcare in the field of plasma-derived therapies.
Through this collaborative endeavour, UNITAR and IPOPI aim to make significant strides in advancing healthcare and capacity-building initiatives. The partnership's collective efforts will lead to tangible and sustainable impacts, benefitting communities worldwide.
We look forward to embarking on this journey together and remain committed to fostering a meaningful and lasting partnership.
About UNITAR
The United Nations Institute for Training and Research (UNITAR) provides innovative learning solutions to individuals, organizations and institutions to enhance global decision-making and support country-level action for shaping a better future. With a strategy fully focused on achieving the Sustainable Development Goals, UNITAR supports Governments to implement the 2030 Agenda. Our mission is to develop the individual, institutional and organizational capacities of countries and other United Nations stakeholders through high-quality learning solutions and related knowledge products and services to enhance decision making and to support country-level action for overcoming global challenges. For more information, please visit https://www.unitar.org.
About IPOPI
The International Patient Organisation for Primary Immunodeficiencies (IPOPI) is a non-profit international organisation that was established in 1992. IPOPI is the leading advocate for primary immunodeficiency (PID) patients worldwide working in collaboration with patients, doctors, politicians, regulators, pharmaceutical industry and other relevant stakeholders. IPOPI is the association of national PID patient organisations dedicated to improving awareness, access to early diagnosis and optimal treatments for primary immunodeficiency patients worldwide through global collaboration. Find out more at https://www.ipopi.org.